

N-OXIDES OF SOME NORDITERPENOID ALKALOIDS

YILI BAI, HARIDUTT K. DESAI, and S. WILLIAM PELLETIER*

*Institute for Natural Products Research and Department of Chemistry,
University of Georgia, Athens, Georgia 30602-2556*


ABSTRACT.—Eight new *N*-oxides [**1–8**] of the norditerpenoid alkaloids aconitine, ajacine, delphinine, delphisine, deltaline, heteratisine, lappaconitine, and *N*-deacetylappaconitine have been prepared with *m*-chloroperbenzoic acid. The structures of these compounds were established on the basis of their spectroscopic data (¹H, ¹³C, DEPT, COSY, HETCOR, and selective INEPT nmr experiments). The complete nmr chemical shift assignments for all eight *N*-oxides are reported. Table 2 shows the differences between the ¹³C-nmr shifts of the *N*-oxides compared with those of the parent alkaloids.

In 1989, we reported the preparation of the *N*-oxides of yunaconitine, crassicauline-A, and some of their derivatives (1). No naturally occurring *N*-oxides of the diterpenoid alkaloids have been reported. In continuation of our pharmacological studies of the diterpenoid alkaloids (2) we report here the preparation and complete nmr assignments for the *N*-oxides of aconitine, ajacine, delphinine, delphisine, deltaline, heteratisine, lappaconitine, and *N*-deacetylappaconitine [**1–8**]. Previously, the *N*-oxides were prepared (1) by refluxing a CHCl₃ solution of the alkaloid and *m*-CPBA (excess). Now we report the preparation of the *N*-oxides **1–8** by carrying out the reactions at room temperature and in fairly good yields.

All the *N*-oxides reported in this work were easily formed (see Experimental) and were found to be stable under the conditions used in their handling. They were all found to be more polar on tlc plates (Al₂O₃, EM-1103 and 1104) compared with their starting materials and were soluble in CHCl₃ except for the low solubility of heteratisine-*N*-oxide [**6**].

The differences between the ¹H- and ¹³C-nmr chemical shifts of **1–8** compared with those of their parent alkaloids are remarkable. These changes in the chemical shifts are due to the bonding of the lone electron pair of the *N*-atom (see Table 2). Table 2 shows that the ¹³C-nmr chemical shifts of all the carbons (i.e., C-17, C-19, and C-20) directly attached to

the *N*-atom are shifted downfield by 12–20 ppm, while C-21 (*N*-CH₂CH₃) moves 5–6 ppm upfield. In the ¹H-nmr spectrum, H₃-21, which generally appears as a triplet around 1–1.2 ppm suffers a deshielding effect and moves to about 1.4–1.5 ppm. The nmr chemical shift assignments for the *N*-oxides **1–8** are based on the study of their ¹H-, ¹³C-, DEPT, COSY, HETCOR, and selective INEPT nmr spectra. (For ¹³C-nmr assignments, see Table 1, and for ¹H-nmr assignments, see the Experimental.) The unambiguous ¹³C-nmr assignments for C-17 (methine), C-19 (methylene), and C-20 (methylene) are based on the study of DEPT, 2D, and selective INEPT nmr experiments. Thus, in the case of deltaline *N*-oxide [**5**], when H₃-21 (Me of the *N*-Et, δ 1.42) was selectively pulsed, a signal at δ 69.6 (t) showed a response; this signal can be assigned to C-20, two bonds away. When H₃-18 (δ 0.92) was selectively pulsed, the responses shown were for the carbon signals at δ 75.3 (t), 48.5 (d), 35.9 (s), and 35.6 (t) and these signals could be assigned to C-19, C-5, C-4, and C-3, respectively. Only C-4 is two bonds away and the other three carbons are three bonds away from H₃-18. C-17 was assigned the value of δ 77.5 (methine) which responded when H-1, overlapped under a signal at δ 3.28 (3H, s, OMe-1), was selectively pulsed. The spectral data obtained for each *N*-oxide support their respective structures. The pharmacological properties of these *N*-oxides, along



with other diterpenoid alkaloids, will be reported elsewhere.

EXPERIMENTAL

GENERAL EXPERIMENTAL PROCEDURES.—Optical rotations were measured on a Perkin-Elmer model 141 polarimeter in CHCl_3 . Ir spectra were taken on a Perkin-Elmer model 1420 spectrophotometer in nujol. ^1H -, ^{13}C - (including DEPT), and 2D nmr spectra were recorded in CDCl_3 on Bruker AC-250 and AC-300 instruments equipped with the standard Bruker software. The pulse sequence employed for selective INEPT data was as given in Desai and Pelletier (3). Ms were recorded on a Finnigan Quadrupole 4023 instrument at 70 eV.

Isolation of the reaction products was carried out by separation on an Al_2O_3 rotor (1 mm, EM-1104) of a Chromatotron (4).

GENERAL PROCEDURES FOR PREPARING N-OXIDES.—To a CHCl_3 solution of *m*-CPBA (7–10 ml), a CHCl_3 solution of the norditerpenoid alkaloid was added at room temperature. The reaction mixture was stirred at room temperature for 3 h. The reaction solution was then passed through a small column of basic Al_2O_3 (Woelm, activity-III) and the column was eluted with more CHCl_3 . This step eliminated the residual excess of *m*-CPBA and benzoic acid from the reaction mixture. The CHCl_3 eluate was then evaporated to dryness *in vacuo* and the residue was fractionated on an Al_2O_3 rotor of a

TABLE 1. ¹³C-Nmr Chemical Shifts and Assignments for *N*-Oxides 1-8.

Carbon	Compound							
	1	2	3	4	5	6'	7	8
C-1	83.7	83.8	85.2	72.2	77.5	87.1	85.7	86.0
C-2	33.6	20.3	23.8	27.8	24.1	25.6	23.0	23.1
C-3	68.1	31.2	34.0	28.2	35.6	37.1	31.0	31.2
C-4	44.1	39.3	40.9	38.2	35.9	38.5	84.9	83.1
C-5	43.7	50.4	47.6	42.7	48.8	57.6	47.1	47.4
C-6	82.1	88.2	81.5	82.9	78.1	71.7	22.3	22.3
C-7	49.2	86.8	53.9	52.4	87.9	54.0	52.4	52.4
C-8	90.7	77.5	84.0	84.7	82.1	77.8	74.7	74.8
C-9	44.9	42.0	44.4	43.0	49.8	51.0	77.9	77.9
C-10	43.7	45.8	43.2	46.5	83.7	45.7	50.8	50.9
C-11	51.2	51.7	51.2	54.7	56.5	51.1	51.4	51.4
C-12	36.3	30.2	36.1	30.5	40.7	29.8	27.0	27.2
C-13	73.6	38.6	74.5	38.1	36.6	76.7	35.4	35.5
C-14	78.3	83.8	78.1	75.1	81.2	175.5	89.0	89.1
C-15	78.5	34.4	38.5	37.5	34.1	33.9	43.6	43.7
C-16	89.3	82.8	82.6	81.7	80.7	31.1	81.9	82.0
C-17	77.9	77.2	79.4	77.4	77.5	78.9	76.5	76.4
C-18	73.7	71.4	79.6	79.1	25.9	26.4	—	—
C-19	60.3	69.8	73.9	68.6	75.3	77.7	74.8	75.4
C-20	65.6	67.3	62.6	65.4	69.6	67.5	66.6	66.6
C-21	7.6	8.1	—	7.3	8.7	8.2	7.8	7.8
OCH ₃ -1	56.6	56.3	56.1	—	56.2	56.7	57.0	57.1
OCH ₃ -6	58.6	57.9	58.0	58.5	—	—	—	—
OCH ₃ -14	—	59.7	—	—	57.7	—	57.7	57.8
OCH ₃ -16	61.3	56.3	58.8	56.6	56.2	—	56.0	56.0
OCH ₃ -18	58.7	—	59.0	59.2	—	—	—	—
O-CH ₂ -O	—	—	—	—	93.8	—	—	—
OAc-6	—	—	—	—	169.8	—	—	—
	—	—	—	—	21.4	—	—	—
OAc-8	172.4	—	169.9	169.9	—	—	—	—
	21.1	—	21.3	22.1	—	—	—	—
OAc-14	—	—	—	170.5	—	—	—	—
	—	—	—	21.1	—	—	—	—
NHAc	—	169.2	—	—	—	—	169.1	—
	—	25.5	—	—	—	—	25.4	—
C=O (aromatic)	165.9	167.8	166.2	—	—	—	167.1	166.9
1'	129.4	114.4	129.8	—	—	—	114.7	110.5
2'	129.4	141.8	129.6	—	—	—	141.7	150.8
3'	128.6	120.6	128.4	—	—	—	120.3	116.7
4'	133.3	135.0	133.1	—	—	—	134.8	134.2
5'	128.6	122.4	128.4	—	—	—	122.2	116.0
6'	129.4	130.3	129.6	—	—	—	130.7	131.1

¹In CD₃OD.

Chromatotron. The tlc homogeneous fractions were combined and the purity of the combined fraction was determined by examining its nmr spectra (¹H and ¹³C) and the tlc behavior in different solvent systems. In all the reactions the major compounds isolated were the *N*-oxides of the starting material except for the lycocotnine-type alkaloids ajacine and *N*-deacetylappaconitine. All the *N*-oxides reported here are amorphous white solids. The samples of all the alkaloids used for this work were authentic samples from our alkaloid collection.

Aconitine-N-oxide [1].—Aconitine (150 mg)

was treated with *m*-CPBA (250 mg) as described above to give compound 1 (C₃₄H₄₇NO₁₂, 67 mg, 40%); [α]_D -6.0° (c=0.35); ir ν max 3490, 1725, 1715, 1280, 1095 cm⁻¹; eims *m/z* 554 (0.6), 115 (0.5), 105 (54), 86 (48), 84 (100); ¹H nmr δ 1.42 (3H, t, *J*=7.2 Hz, NCH₂Me), 1.43 (3H, s, OAc-8), 2.38 (1H, d, *J*=6.5 Hz, H-5), 2.77 (1H, d, H-12), 2.90 (1H, t, H-9), 3.21 (3H, s, OMe-6), 3.24 (3H, s, OMe-1), 3.26 (3H, s, OMe-18), 3.43 (1H, br s, H-17), 3.68 (3H, s, OMe-16), 3.73 (1H, m, H-3β), 4.08 (1H, d, *J*=6.5 Hz, H-6β), 4.37 (1H, d, *J*=2.6 Hz, OH-15), 4.46 (1H, dd, *J*=5.3 and 2.6 Hz, H-15β), 4.86 (1H, d, *J*=5.0 Hz, H-14β), 7.43 (2H, t, *J*=7.5 Hz, H-3', -5'), 7.56 (1H, t,

TABLE 2. ^{13}C -Nmr Data Differences^a Between *N*-Oxides and Their Parent Alkaloids.

Carbon	Compound							
	1	2	3	4	5	6 ^b	7	8
C-1	+1.3	-0.1	+0.3	+0.2	+0.2	+3.6	+1.5	+2.9
C-2	-0.3	-5.8	-2.5	-2.2	-3.1	-1.3	-3.2	-3.2
C-3	-2.9	-0.9	-0.6	-1.2	-0.9	+0.3	-0.9	-0.9
C-4	+0.9	+1.1	+1.7	+0.2	+2.2	+3.8	+0.2	-1.4
C-5	-3.2	-0.1	-1.0	-1.1	-1.6	-0.7	-1.5	-2.6
C-6	-1.3	-2.8	-1.4	-1.1	-1.1	-1.2	-4.5	-4.6
C-7	+4.4	-1.8	+5.9	+4.6	-3.7	+3.3	+4.8	+4.7
C-8	-1.4	0	-1.4	-1.1	+0.7	+2.4	-0.9	-1.0
C-9	+0.7	-1.3	-0.6	-0.1	-0.6	+1.6	-0.7	-0.8
C-10	+2.8	-0.3	+2.2	+3.4	-0.1	+2.9	+1.8	+2.2
C-11	+1.2	+2.6	+1.0	+5.0	+0.5	+1.8	+0.4	+0.4
C-12	+0.4	+1.6	+0.7	+1.1	+1.3	+0.6	+2.8	+3.1
C-13	-0.4	+1.0	-0.3	-0.3	-1.9	+0.9	-1.0	-1.0
C-14	-0.6	-0.1	-0.6	-0.4	-0.5	-0.5	-1.2	-1.3
C-15	-0.3	+0.6	-0.7	-0.8	-0.7	-0.8	-1.3	-1.2
C-16	-0.8	+0.2	-0.9	-0.9	-0.8	+2.1	-1.0	-1.1
C-17	+17.0	+12.7	+16.1	+14.8	+14.0	+16.7	+15.0	+14.7
C-18	-2.5	+1.6	-0.6	-0.6	+0.2	+0.4	—	—
C-19	+13.3	+17.3	+17.9	+12.0	+18.4	+19.9	+19.3	+19.6
C-20	+16.7	+16.3	+20.1	+17.2	+19.4	+18.5	+16.7	+17.6
C-21	-5.8	-5.9	—	-5.6	-5.1	-5.3	-5.7	-5.8
OCH ₃ -1	+0.7	+0.5	0	—	+0.9	+1.5	+0.5	+0.9
OCH ₃ -6	+0.6	+0.1	+0.4	+0.5	—	—	—	—
OCH ₃ -14	—	+1.7	—	—	0	—	-0.2	-0.2
OCH ₃ -16	+0.2	0	+0.2	0	0	—	-0.1	-0.5
OCH ₃ -18	-0.4	—	0	+0.1	—	—	—	—
O-CH ₂ -O	—	—	—	—	-0.1	—	—	—
OAc-6	—	—	—	—	0	—	—	—
	—	—	—	—	-0.3	—	—	—
OAc-8	+0.1	—	+0.5	+0.4	—	—	—	—
	-0.3	—	-0.2	-0.1	—	—	—	—
OAc-14	—	—	—	-0.1	—	—	—	—
	—	—	—	-0.1	—	—	—	—
NHAc	—	+0.2	—	—	—	—	-0.4	—
	—	0	—	—	—	—	-0.2	—
C=O (aromatic)	0	-0.3	+0.3	—	—	—	-0.6	-0.8
1'	-0.4	-0.1	+0.1	—	—	—	-1.8	-1.7
2'	-0.2	-0.1	+0.3	—	—	—	-0.1	+0.1
3'	0	0	+0.3	—	—	—	-0.1	-0.1
4'	+0.1	0	+0.4	—	—	—	+0.2	+0.2
5'	0	-0.1	+0.3	—	—	—	-0.4	-0.4
6'	-0.2	0	+0.3	—	—	—	-0.6	-0.7

^a(+) Indicates a downfield shift and (-) an upfield shift.

^bSolvents are different (CDCl₃ for heteratisine, and CD₃OD for its *N*-oxide).

$J=7.5$ Hz, H-4'), 8.02 (2H, d, $J=7.5$ Hz, H-2', -6'). For ^{13}C -nmr chemical shift assignments, see Table 1.

Ajacine-N-oxide [2].—Ajacine (150 mg) was treated with *m*-CPBA (250 mg) as described above to give compound **2** (C₃₄H₄₈N₂O₁₀, 23 mg, 20%); $[\alpha]_D^{25} +29.3^\circ$ ($c=0.195$); ir ν max 3400, 1690, 1251, 1082, 665 cm⁻¹; ^1H nmr δ 1.43 (3H, t, $J=7.2$ Hz, NCH₂Me), 2.24 (3H, s, NHAc), 3.30, 3.36, 3.44 (3H each, s, 3×OMe), 3.63 (1H, t, $J=4.5$ Hz, H-14 β), 4.16, 4.33 (1H each, d, $J=13.0$ Hz, H₂-18), 4.62 (2H, dd, H₂-19), 4.73 (1H, br s, H-6 α), 7.09 (1H, t, $J=7.6$ Hz, H-5'),

7.56 (1H, t, $J=7.8$ Hz, H-4'), 7.97 (1H, d, $J=8.1$ Hz, H-6'), 8.70 (1H, d, $J=8.0$ Hz, H-3'), 10.98 (1H, br s, NHAc). For ^{13}C -nmr chemical shift assignments, see Table 1.

Delphinine-N-oxide [3].—Delphinine (200 mg) was treated with *m*-CPBA (350 mg) as described above to give compound **3** (C₃₃H₄₅NO₁₀, 167 mg, 81.3%); $[\alpha]_D^{25} +3.85^\circ$ ($c=0.53$); ir ν max 1725, 1715 cm⁻¹; eims m/z 584 [M-31]⁺ (8), 508 (12), 105 (100); ^1H nmr δ 1.25 (3H, s, OAc-8), 1.65 (1H, m, H-3), 2.40 (1H, br d, $J=4.2$ Hz, H-10 β), 2.44, 2.95 (1H each, dd, $J=16.1$ Hz, H₂-15), 2.81 (1H, br t, H-9), 3.12 (3H, s, OMe-6),

3.20 (3H, s, OMe-18), 3.22 (3H, s, OMe-1), 3.28 (1H, br s, H-7), 3.31 (3H, s, *N*-Me), 3.45 (3H, s, OMe-16), 3.35, 3.73 (1H each, *d*, $J=11$ Hz, H₂-19), 7.42 (2H, *t*, $J=7.6$ Hz, H-3', -5'), 7.52 (1H, *t*, $J=7.5$ Hz, H-4'), 8.02 (2H, *d*, $J=7.7$ Hz, H-2', -6'). For ¹³C-nmr chemical shift assignments, see Table 1.

Delphisine-N-oxide [4].—Delphisine (100 mg) was treated with *m*-CPBA (200 mg) as described above to yield compound **4** (C₂₈H₄₃NO₉, 62 mg, 59%); [α]_D -2.47° ($c=0.35$); *ir* ν max 3490, 1725, 1715, 1280, 1095 cm⁻¹; eims *m/z* 520 [M-17]⁻ (0.03), 504 [M-16-17]⁺ (4), 488 (1), 476 (1), 462 (2), 444 (2), 432 (1), 417 (5), 71 (13), 43 (100); ¹H nmr δ 1.44 (3H, *t*, $J=7.1$ Hz, NCH₂Me), 1.55 (m, H-3), 1.84, 1.90 (2H, 2×m, H₂-12), 1.97 (3H, s, OAc-8), 2.04 (3H, s, OAc-14), 2.08, 2.15 (2H, 2×m, H₂-15), 2.31 (1H, s, H-5), 2.42 (1H, m, H-13), 2.52 (1H, m, H-9), 3.18 (1H, br s, H-17), 3.28 (3H, s, OMe-6), 3.28 (3H, s, OMe-18), 3.31 (3H, s, OMe-16), 3.62 (1H, m, H-1β), 4.09 (1H, *d*, $J=6.5$ Hz, H-6β), 4.80 (1H, *t*, $J=4.7$ Hz, H-14β). For ¹³C-nmr chemical shift assignments, see Table 1.

Deltaline-N-oxide [5].—Deltaline (175 mg) was treated with *m*-CPBA (250 mg) to furnish compound **5** after the usual protocol mentioned in the general procedure. Compound **5** (C₂₇H₄₁NO₉, 173 mg, 95.8%); [α]_D -33.5° ($c=0.39$); *ir* ν max 3400, 1740, 1245, 1085, 800 cm⁻¹; eims *m/z* 476 [M-O-OMe]⁻ (5), 465 [M+1-OAc]⁺ (16), 448 [M-O-OAc]⁺ (27), 434 [*m/z* 465-OMe]⁻ (7), 43 (100); ¹H nmr δ 0.92 (3H, s, Me-18), 1.42 (3H, *t*, N-CH₂Me), 2.07 (1H, s, OAc), 3.26 (3H, s, OMe-1), 3.27 (3H, s, OMe-16), 3.40 (3H, s, OMe-14), 3.51 (1H, br s, H-17), 4.16 (1H, *t*, $J=4.8$ Hz, H-14β), 4.93 (2H, s, O-CH₂-O), 5.34 (1H, s, H-6). For ¹³C-nmr chemical shift assignments, see Table 1.

Heteratisine-N-oxide [6].—Heteratisine (110 mg) was treated with *m*-CPBA (200 mg) to provide compound **6** after following the general procedure. Compound **6** (C₂₂H₃₃NO₆, 64 mg, 55.8%); [α]_D +19.9° ($c=0.21$); *ir* ν max 3490, 1730 cm⁻¹; eims *m/z* 377 [M-30]⁻ (0.75), 360 [M-30-17]⁻ (16), 344 (18), 330 (31), 272 (14); ¹H nmr δ 0.94 (3H, s, Me-4), 1.25 (3H, *t*, $J=7.0$ Hz, NCH₂Me), 1.48 (1H, br s, H-5), 3.16 (3H, s, OMe-1), 3.63 (1H, *d*, $J=7.2$ Hz, H-9), 3.72 (1H, br s, H-17),

4.38 (1H, *d*, $J=7.4$ Hz, H-6β), 4.62 (1H, *t*, $J=6.8$ Hz, H-13). For ¹³C-nmr chemical shift assignments, see Table 1.

Lappaconitine-N-oxide [7].—Lappaconitine (100 mg) was treated with *m*-CPBA (190 mg) to furnish compound **7** after following the usual protocol. Compound **7** (C₃₂H₄₄N₂O₉, 87 mg, 84.7%); [α]_D +26.8° ($c=0.38$); eims *m/z* 504 (6), 417 (2), 376 (4), 83 (100), 43 (90); ¹H nmr δ 1.48 (3H, *t*, $J=6.8$ Hz, NCH₂Me), 2.16 (3H, s, NHAc), 3.25 (3H, s, OMe-1), 3.27 (3H, s, OMe-16), 3.35 (3H, s, OMe-14), 3.65, 4.26 (1H each, *d*, $J=14.0$ Hz, H₂-19), 6.97 (1H, *t*, $J=7.5$ Hz, H-5'), 7.47 (1H, *t*, $J=7.9$ Hz, H-4'), 7.82 (1H, *d*, $J=7.9$ Hz, H-6'), 8.61 (1H, *d*, $J=8.4$ Hz, H-3'), 10.86 (1H, br s, NH). For ¹³C-nmr chemical shift assignments, see Table 1.

***N*-deacetylappaconitine-N-oxide [8].**—An aliquot (100 mg) of compound **7** was dissolved in 13 ml of 2% HCl (aqueous) and the solution was refluxed for 2 h. The reaction solution was worked up and purified to give compound **8** (C₃₀H₄₂N₂O₈, 50 mg, 48.5%); [α]_D +15.3° ($c=0.37$); *ir* ν max 3350, 3450, 1680 cm⁻¹; eims *m/z* 393 (15), 376 (48), 342 (11), 84 (100); ¹H nmr δ 1.49 (3H, *t*, $J=6.8$ Hz, NCH₂Me), 3.27 (3H, s, OMe-16), 3.29 (3H, s, OMe-1), 3.39 (3H, s, OMe-14), 3.51 (1H, br s, H-17), 3.63, 4.34 (1H, each, *d*, $J=14.3$ Hz, H₂-19), 6.61 (1H, *d*, $J=8.0$ Hz, H-3'), 7.21 (1H, *t*, $J=8.0$ Hz, H-4'), 7.67 (1H, *d*, $J=8.0$ Hz, H-6'). For ¹³C-nmr chemical shift assignments, see Table 1.

ACKNOWLEDGMENTS

This work was supported by Grant HL 32562 from the National Institutes of Health. We thank Mr. Courtney Pape for the mass spectra.

LITERATURE CITED

1. F.P. Wang and S.W. Pelletier, *West China J. Pharm. Sci.*, **4**, 193 (1989).
2. Y. Bai, H.K. Desai, and S.W. Pelletier, *J. Nat. Prod.*, **57**, 963 (1994).
3. H.K. Desai and S.W. Pelletier, *J. Nat. Prod.*, **56**, 1140 (1993).
4. H.K. Desai, E.R. Trumbull, and S.W. Pelletier, *J. Chromatogr.*, **366**, 439 (1986).

Received 31 October 1994